2
|
Goto A, Yamamoto S, Igari T, Matsumoto SI, Chisaki I, Iida K, Nakayama M, Oda A, Kakoi Y, Uchida A, Miyata K, Nishikawa M, Nagata T, Kusuhara H, Yokota T, Hirabayashi H. Quantitative Model Analysis and Simulation of Pharmacokinetics and Metastasis-Associated Lung Adenocarcinoma 1 RNA Knockdown Effect After Systemic Administration of Cholesterol-Conjugated DNA/RNA Heteroduplex Oligonucleotide Crossing Blood-Brain Barrier of Mice. J Pharmacol Exp Ther 2023; 384:197-204. [PMID: 36273821 DOI: 10.1124/jpet.122.001331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2022] [Revised: 09/07/2022] [Accepted: 09/29/2022] [Indexed: 11/18/2022] Open
Abstract
The cholesterol-conjugated heteroduplex oligonucleotide (Chol-HDO) is a double-stranded complex; it comprises an antisense oligonucleotide (ASO) and its complementary strand with a cholesterol ligand. Chol-HDO is a powerful tool for achieving target RNA knockdown in the brains of mice after systemic injection. Here, a quantitative model analysis was conducted to characterize the relationship between the pharmacokinetics (PK) and pharmacodynamics (PD), non-coding RNA metastasis-associated lung adenocarcinoma 1 (Malat1) RNA, of Chol-HDO, in a time-dependent manner. The established PK model could describe regional differences in the observed brain concentration-time profiles. Incorporating the PD model enabled the unique knockdown profiles in the brain to be explained in terms of the time delay after single dosing and enhancement following repeated dosing. Moreover, sensitivity analysis of PK exposure/persistency, target RNA turnover, and knockdown potency identified key factors for the efficient and sustained target RNA knockdown in the brain. The simulation of an adequate dosing regimen quantitatively supported the benefit of Chol-HDO in terms of achieving a suitable dosing interval. This was achieved via sufficient and sustained brain exposure and subsequent strong and sustained target RNA knockdown in the brain, even after systemic injection. The present study provides new insights into drug discoveries and development strategies for HDO in patients with neurogenic disorders. SIGNIFICANCE STATEMENT: The quantitative model analysis presented here characterized the PK/PD relationship of Chol-HDO, enabled its simulation under various conditions or assumptions, and identified key factors for efficient and sustained RNA knockdown, such as PK exposure and persistency. Chol-HDO appears to be an efficient drug delivery system for the systemic administration of desired drugs to brain targets.
Collapse
Affiliation(s)
- Akihiko Goto
- Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.G., S.Y., T.I., S.M., I.C., K.I., Mi.N., H.H.); Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.O., Y.K.); Asia New Chemical Entity Production Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.U., K.M.); Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan (Ma.N.); Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (H.K.); and Department of Neurology and Neurologic Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. (T.N., T.Y.)
| | - Syunsuke Yamamoto
- Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.G., S.Y., T.I., S.M., I.C., K.I., Mi.N., H.H.); Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.O., Y.K.); Asia New Chemical Entity Production Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.U., K.M.); Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan (Ma.N.); Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (H.K.); and Department of Neurology and Neurologic Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. (T.N., T.Y.)
| | - Tomoko Igari
- Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.G., S.Y., T.I., S.M., I.C., K.I., Mi.N., H.H.); Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.O., Y.K.); Asia New Chemical Entity Production Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.U., K.M.); Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan (Ma.N.); Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (H.K.); and Department of Neurology and Neurologic Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. (T.N., T.Y.)
| | - Shin-Ichi Matsumoto
- Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.G., S.Y., T.I., S.M., I.C., K.I., Mi.N., H.H.); Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.O., Y.K.); Asia New Chemical Entity Production Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.U., K.M.); Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan (Ma.N.); Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (H.K.); and Department of Neurology and Neurologic Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. (T.N., T.Y.)
| | - Ikumi Chisaki
- Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.G., S.Y., T.I., S.M., I.C., K.I., Mi.N., H.H.); Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.O., Y.K.); Asia New Chemical Entity Production Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.U., K.M.); Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan (Ma.N.); Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (H.K.); and Department of Neurology and Neurologic Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. (T.N., T.Y.)
| | - Koichi Iida
- Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.G., S.Y., T.I., S.M., I.C., K.I., Mi.N., H.H.); Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.O., Y.K.); Asia New Chemical Entity Production Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.U., K.M.); Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan (Ma.N.); Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (H.K.); and Department of Neurology and Neurologic Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. (T.N., T.Y.)
| | - Miyu Nakayama
- Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.G., S.Y., T.I., S.M., I.C., K.I., Mi.N., H.H.); Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.O., Y.K.); Asia New Chemical Entity Production Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.U., K.M.); Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan (Ma.N.); Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (H.K.); and Department of Neurology and Neurologic Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. (T.N., T.Y.)
| | - Akira Oda
- Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.G., S.Y., T.I., S.M., I.C., K.I., Mi.N., H.H.); Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.O., Y.K.); Asia New Chemical Entity Production Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.U., K.M.); Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan (Ma.N.); Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (H.K.); and Department of Neurology and Neurologic Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. (T.N., T.Y.)
| | - Yuuichi Kakoi
- Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.G., S.Y., T.I., S.M., I.C., K.I., Mi.N., H.H.); Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.O., Y.K.); Asia New Chemical Entity Production Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.U., K.M.); Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan (Ma.N.); Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (H.K.); and Department of Neurology and Neurologic Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. (T.N., T.Y.)
| | - Akio Uchida
- Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.G., S.Y., T.I., S.M., I.C., K.I., Mi.N., H.H.); Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.O., Y.K.); Asia New Chemical Entity Production Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.U., K.M.); Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan (Ma.N.); Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (H.K.); and Department of Neurology and Neurologic Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. (T.N., T.Y.)
| | - Kenichi Miyata
- Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.G., S.Y., T.I., S.M., I.C., K.I., Mi.N., H.H.); Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.O., Y.K.); Asia New Chemical Entity Production Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.U., K.M.); Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan (Ma.N.); Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (H.K.); and Department of Neurology and Neurologic Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. (T.N., T.Y.)
| | - Makiya Nishikawa
- Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.G., S.Y., T.I., S.M., I.C., K.I., Mi.N., H.H.); Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.O., Y.K.); Asia New Chemical Entity Production Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.U., K.M.); Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan (Ma.N.); Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (H.K.); and Department of Neurology and Neurologic Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. (T.N., T.Y.)
| | - Tetsuya Nagata
- Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.G., S.Y., T.I., S.M., I.C., K.I., Mi.N., H.H.); Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.O., Y.K.); Asia New Chemical Entity Production Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.U., K.M.); Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan (Ma.N.); Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (H.K.); and Department of Neurology and Neurologic Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. (T.N., T.Y.)
| | - Hiroyuki Kusuhara
- Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.G., S.Y., T.I., S.M., I.C., K.I., Mi.N., H.H.); Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.O., Y.K.); Asia New Chemical Entity Production Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.U., K.M.); Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan (Ma.N.); Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (H.K.); and Department of Neurology and Neurologic Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. (T.N., T.Y.)
| | - Takanori Yokota
- Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.G., S.Y., T.I., S.M., I.C., K.I., Mi.N., H.H.); Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.O., Y.K.); Asia New Chemical Entity Production Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.U., K.M.); Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan (Ma.N.); Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (H.K.); and Department of Neurology and Neurologic Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. (T.N., T.Y.)
| | - Hideki Hirabayashi
- Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.G., S.Y., T.I., S.M., I.C., K.I., Mi.N., H.H.); Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.O., Y.K.); Asia New Chemical Entity Production Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan (A.U., K.M.); Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan (Ma.N.); Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (H.K.); and Department of Neurology and Neurologic Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. (T.N., T.Y.)
| |
Collapse
|